365 related articles for article (PubMed ID: 26229107)
1. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
[TBL] [Abstract][Full Text] [Related]
3. The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.
Liu F; You X; Wang Y; Liu Q; Liu Y; Zhang S; Chen L; Zhang X; Ye L
Carcinogenesis; 2014 May; 35(5):1144-53. PubMed ID: 24464787
[TBL] [Abstract][Full Text] [Related]
4. The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells.
Liu S; Li L; Zhang Y; Zhang Y; Zhao Y; You X; Lin Z; Zhang X; Ye L
J Biol Chem; 2012 Aug; 287(36):30228-39. PubMed ID: 22740693
[TBL] [Abstract][Full Text] [Related]
5. Oncoprotein HBXIP Modulates Abnormal Lipid Metabolism and Growth of Breast Cancer Cells by Activating the LXRs/SREBP-1c/FAS Signaling Cascade.
Zhao Y; Li H; Zhang Y; Li L; Fang R; Li Y; Liu Q; Zhang W; Qiu L; Liu F; Zhang X; Ye L
Cancer Res; 2016 Aug; 76(16):4696-707. PubMed ID: 26980761
[TBL] [Abstract][Full Text] [Related]
6. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer.
Wang Y; Fang R; Cui M; Zhang W; Bai X; Wang H; Liu B; Zhang X; Ye L
Cancer Lett; 2017 Jan; 385():234-242. PubMed ID: 27765671
[TBL] [Abstract][Full Text] [Related]
7. The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells.
Yue L; Li L; Liu F; Hu N; Zhang W; Bai X; Li Y; Zhang Y; Fu L; Zhang X; Ye L
Carcinogenesis; 2013 Apr; 34(4):927-35. PubMed ID: 23291272
[TBL] [Abstract][Full Text] [Related]
8. The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer.
Liu F; Zhang W; You X; Liu Y; Li Y; Wang Z; Wang Y; Zhang X; Ye L
Oncotarget; 2015 Sep; 6(29):27199-213. PubMed ID: 26309161
[TBL] [Abstract][Full Text] [Related]
9. The oncoprotein HBXIP up-regulates FGF4 through activating transcriptional factor Sp1 to promote the migration of breast cancer cells.
Shi H; Li Y; Feng G; Li L; Fang R; Wang Z; Qu J; Ding P; Zhang X; Ye L
Biochem Biophys Res Commun; 2016 Feb; 471(1):89-94. PubMed ID: 26828265
[TBL] [Abstract][Full Text] [Related]
10. The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells.
Zhang Y; Zhao Y; Li L; Shen Y; Cai X; Zhang X; Ye L
Biochem Biophys Res Commun; 2013 May; 434(2):305-10. PubMed ID: 23537647
[TBL] [Abstract][Full Text] [Related]
11. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells.
Shi H; Fang R; Li Y; Li L; Zhang W; Wang H; Chen F; Zhang S; Zhang X; Ye L
Cancer Lett; 2016 Nov; 382(2):147-156. PubMed ID: 27609066
[TBL] [Abstract][Full Text] [Related]
12. The oncoprotein HBXIP upregulates Lin28B via activating TF II D to promote proliferation of breast cancer cells.
Liu Q; Bai X; Li H; Zhang Y; Zhao Y; Zhang X; Ye L
Int J Cancer; 2013 Sep; 133(6):1310-22. PubMed ID: 23494474
[TBL] [Abstract][Full Text] [Related]
13. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
Cai X; Wang X; Cao C; Gao Y; Zhang S; Yang Z; Liu Y; Zhang X; Zhang W; Ye L
Cancer Lett; 2018 Feb; 415():11-19. PubMed ID: 29174803
[TBL] [Abstract][Full Text] [Related]
14. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
15. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis.
Zhou XL; Zhu CY; Wu ZG; Guo X; Zou W
Oncogene; 2019 May; 38(21):4028-4046. PubMed ID: 30692632
[TBL] [Abstract][Full Text] [Related]
16. Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.
Li L; Fang R; Liu B; Shi H; Wang Y; Zhang W; Zhang X; Ye L
Oncogene; 2016 Aug; 35(31):4048-57. PubMed ID: 26657153
[TBL] [Abstract][Full Text] [Related]
17. miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8.
Hu N; Zhang J; Cui W; Kong G; Zhang S; Yue L; Bai X; Zhang Z; Zhang W; Zhang X; Ye L
J Biol Chem; 2011 Apr; 286(15):13714-22. PubMed ID: 21343296
[TBL] [Abstract][Full Text] [Related]
18. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation.
Brekman A; Singh KE; Polotskaia A; Kundu N; Bargonetti J
Breast Cancer Res; 2011 Jan; 13(1):R3. PubMed ID: 21223569
[TBL] [Abstract][Full Text] [Related]
19. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
[TBL] [Abstract][Full Text] [Related]
20. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
